Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more
Immutep Limited (PRRUF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.117x
Based on the latest financial reports, Immutep Limited (PRRUF) has a cash flow conversion efficiency ratio of -0.117x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.75 Million) by net assets ($143.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immutep Limited - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Immutep Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Immutep Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen MinDe Electronics Technology Ltd
SHE:300656
|
0.020x |
|
Genfit S.A.
NASDAQ:GNFT
|
-0.574x |
|
Mills Estruturas e Serviços de Engenharia S.A
SA:MILS3
|
0.000x |
|
Linzhou Heavy Machinery Group Co Ltd
SHE:002535
|
0.027x |
|
Wuhan Sante Cableway Group Co Ltd
SHE:002159
|
0.074x |
|
Hanson International Tbk
JK:MYRX
|
0.018x |
|
Sanyou Corporation Limited
SHE:300932
|
N/A |
|
Liaoning SG Automotive Group Co Ltd
SHG:600303
|
-0.068x |
Annual Cash Flow Conversion Efficiency for Immutep Limited (2008–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Limited from 2008 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $143.64 Million | $-62.05 Million | -0.432x | -135.12% |
| 2024-06-30 | $189.52 Million | $-34.82 Million | -0.184x | +29.08% |
| 2023-06-30 | $136.47 Million | $-35.36 Million | -0.259x | +19.37% |
| 2022-06-30 | $94.08 Million | $-30.23 Million | -0.321x | -33.47% |
| 2021-06-30 | $73.27 Million | $-17.64 Million | -0.241x | +26.04% |
| 2020-06-30 | $33.30 Million | $-10.84 Million | -0.326x | +48.07% |
| 2019-06-30 | $24.39 Million | $-15.29 Million | -0.627x | -170.19% |
| 2018-06-30 | $33.52 Million | $-7.78 Million | -0.232x | +27.64% |
| 2017-06-30 | $26.53 Million | $-8.51 Million | -0.321x | -0.12% |
| 2016-06-30 | $35.32 Million | $-11.31 Million | -0.320x | -1.53% |
| 2015-06-30 | $24.69 Million | $-7.79 Million | -0.315x | +49.92% |
| 2014-06-30 | $22.59 Million | $-14.23 Million | -0.630x | -14.85% |
| 2013-06-30 | $29.25 Million | $-16.04 Million | -0.548x | -6.56% |
| 2012-06-30 | $37.16 Million | $-19.12 Million | -0.515x | -190.62% |
| 2011-06-30 | $55.10 Million | $-9.76 Million | -0.177x | +54.00% |
| 2010-06-30 | $16.79 Million | $-6.46 Million | -0.385x | +62.96% |
| 2009-06-30 | $1.81 Million | $-1.88 Million | -1.039x | -76.06% |
| 2008-06-30 | $2.63 Million | $-1.55 Million | -0.590x | -- |